UBS Reiterates Buy Rating on Repligen (RGEN) as Incrementally Positive on Outlook

September 29, 2026 9:02 AM

UBS analyst Douglas Schenkel reiterated a Buy rating and $225.00 price target on Repligen (NASDAQ: RGEN).The analyst commented, "Our recent ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found